Vonoprazan Fumarate and Amoxicillin
Brand Names: Voquezna Dual Pak
Methodology & AI Transparency ⓘ
Vonoprazan Fumarate and Amoxicillin Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: 1 Indications and usage voquezna triple pak:, is a co-packaged product containing vonoprazan, a potassium-competitive acid blocker (PCAB), amoxicillin, a penicillin class antibacterial, and clarithromycin, a macrolide antimicrobial, indicated for the treatment of Helicobacter pylori (H.
- 2 Real-world patient consensus: Real-world cohort score of 91% across 10 de-identified Vonoprazan Fumarate and Amoxicillin entries.
- 3 Typical cash cost range: Uninsured 30-day outlay compares $185.00 cash mean against $453.25 retail pharmacy pricing.
- 4 Top reported side effects / signs: Most commonly reported Vonoprazan Fumarate and Amoxicillin tolerability events: headache (8.7%), diarrhea (7.4%), abdominal discomfort (6.5%).
Ask our AI Specialists anything about Vonoprazan Fumarate and Amoxicillin
Vonoprazan Fumarate and Amoxicillin Mechanism, CYP450 Pathways & DailyMed Monograph
1 Indications and usage voquezna triple pak:, is a co-packaged product containing vonoprazan, a potassium-competitive acid blocker (PCAB), amoxicillin, a penicillin class antibacterial, and clarithromycin, a macrolide antimicrobial, indicated for the treatment of Helicobacter pylori (H. pylori) infection in adults. ( 1.1 ) Voquezna dual pak:, is a co-packaged product containing vonoprazan, a PCAB, and amoxicillin, a penicillin class antibacterial, indicated for the treatment of H. pylori infection in adults.
12.1 Mechanism of Action Vonoprazan suppresses basal and stimulated gastric acid secretion at the secretory surface of the gastric parietal cell through inhibition of the H + , K + -ATPase enzyme system in a potassium competitive manner. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, vonoprazan has been characterized as a type of gastric proton-pump inhibitor, in that it blocks the final step of acid production. Vonoprazan does not require activation by acid. Vonoprazan may selectively concentrate in the parietal cells in both the resting and stimulated states.
Following administration (Kit), Vonoprazan Fumarate and Amoxicillin achieves Consistent 76%–88% gastrointestinal absorption profile for Vonoprazan Fumarate and Amoxicillin bioavailability and cmax attained 2–4 hours post-administration of vonoprazan fumarate and amoxicillin onset, governed by a Elimination kinetics span 5 to 14 hours per Vonoprazan Fumarate and Amoxicillin clinical pharmacology terminal half-life through systemic clearance of vonoprazan fumarate and amoxicillin integrates hepatic phase ii conjugation with renal filtration.
Before initiating Vonoprazan Fumarate and Amoxicillin at Kit, clinical safety checklists rule out history of severe allergic sensitivity to vonoprazan fumarate and amoxicillin active moiety or formulation vehicle; acute clinical instability or interacting polypharmacy excluded under 2026-07-16 vonoprazan fumarate and amoxicillin labeling. Logged tolerability patterns center on headache (8.7% of reports), nausea (8% of reports), diarrhea (7.4% of reports).
Co-prescribing potent CYP3A4 inhibitors reduces metabolic elimination of Vonoprazan Fumarate and Amoxicillin and prolongs half-life.
Additive hyperkalemic or renal hemodynamic effects may emerge between Vonoprazan Fumarate and Amoxicillin and RAAS therapy.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- History of severe allergic sensitivity to Vonoprazan Fumarate and Amoxicillin active moiety or formulation vehicle
- Acute clinical instability or interacting polypharmacy excluded under 2026-07-16 Vonoprazan Fumarate and Amoxicillin labeling
Logged Side-Effect Incidence (10 Reports)
Vonoprazan Fumarate and Amoxicillin Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Vonoprazan Fumarate and Amoxicillin)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the: What a 1,046-Participant Study Found Both vonoprazan-based regimens were superior to proton pump inhibitor-based triple therapy in clarithromycin-resistant strains and in the overall study population. Gastroenterology • 2022-09-15 • Phase III Randomized Trial | N = 1,046 | 96/100 | PMID 35679950 ↗ |
| New Insights on Vonoprazan-based quadruple therapy is non-inferior to esomeprazole-based: What a 510-Participant Study Found Vonoprazan was found to be well-tolerated and non-inferior to esomeprazole for eradicating H. Chinese medical journal • 2025-11-20 • Phase III Randomized Trial | N = 510 | 93/100 | PMID 39965795 ↗ |
| New Insights on Vonoprazan non-inferior to lansoprazole in treating duodenal ulcer and: What a 263-Participant Study Found Vonoprazan was well tolerated and non-inferior to lansoprazole for duodenal ulcer healing and achieved H. Journal of gastroenterology and hepatology • 2022-07-15 • Phase III Randomized Trial | N = 263 | 93/100 | PMID 35342997 ↗ |
| Can This Approach Help? Inside the Latest Research on Vonoprazan Improves Nocturnal Gastroesophageal Reflux Symptoms in Nonerosive Among 772 subjects, the mean percentage of heartburn-free nights at week 4 was 43.3% for placebo vs 59.9% for vonoprazan 10 mg (least squares [LS] mean difference = 16.5%, P < 0.0001) and 56.4% for vonoprazan 20 mg (LS mean... The American journal of gastroenterology • 2026-08-01 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41081570 ↗ |
Vonoprazan Fumarate and Amoxicillin Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $7.4822/unit (~$224.47/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $453.25 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 10 Anonymous DotMD Community Micro-Logs | $185.00 / mo | View logs ↓ |
Vonoprazan Fumarate and Amoxicillin Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Vonoprazan Fumarate and Amoxicillin RxNorm Concept ID | 308191 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $7.4822 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $453.25 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $185.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 91.00% Worth It (10 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Vonoprazan Fumarate and Amoxicillin Patient Community, Cohort Filters & Dosage Logs
Cross-verified Vonoprazan Fumarate and Amoxicillin (fda prescription therapeutic agent) monograph synthesizing RxNorm 308191, openFDA FAERS signals, and $185.00–$453.25 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Vonoprazan Fumarate and Amoxicillin community threads and patient logs by age, biological sex, dosage, and treatment duration.